Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel–prednisone in metastatic castration-resistant prostate cancer

BACKGROUND: Docetaxel–prednisone (DP) is an approved therapy for metastatic castration-resistant prostate cancer (mCRPC). Orteronel (TAK-700) is an investigational, selective, non-steroidal inhibitor of 17,20-lyase, a key enzyme in androgenic hormone production. This phase 1/2 study evaluated ortero...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Invest New Drugs
Main Authors: Petrylak, Daniel P., Gandhi, Jitendra G., Clark, William R., Heath, Elisabeth, Lin, Jianqing, Oh, William K., Agus, David B., Carthon, Bradley, Moran, Susan, Kong, Ning, Suri, Ajit, Bargfrede, Michael, Liu, Glenn
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4390470/
https://ncbi.nlm.nih.gov/pubmed/25556680
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-014-0199-x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados